| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2018-07-05 |
| タイトル |
|
|
タイトル |
EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1 |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hepatitis C virus |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
interferon free |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
daclatasvir |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
asunaprevir |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
α fetoprotein |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.20569/00003587 |
|
ID登録タイプ |
JaLC |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
AJIMINE, Takuma
OHSHIMA, Shigetoshi
GOTO, Takashi
KOMATSU, Masafumi
NAKANE, Kunio
YAGISAWA, Hitoshi
Goto, Mitsuo
NAKAJIMA, Kou
Miura, Masato
FUNAOKA, Masato
HOSHINO, Takao
KURAMITSU, Tomoyuki
FUJISHIMA, Yuukou
WATANABE, Daisuke
Segawa, Daisuke
Inomata, Masaaki
IIJIMA, Katsunori
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1. METHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016. We followed them until 24 weeks after the end of treatment. RESULT : The sustained virological response (SVR) at 24 weeks after the end of treatment rates were 84.2%. In univariate analyses, the Y93 mutation and a history of triple therapy with protease inhibitor reduced the SVR 24 rate. In multivariate analyses, the Y93H mutation, a history of triple therapy with protease inhibitor, and LC status reduced the SVR 24 rate. The most frequently reported adverse event was ALT elevation, noted in 25.7% of patients. 10.7% of patients had T-Bil elevation, 7.1% experienced drug rush, 11.5% experienced respiratory symptoms, 10.3% developed a fever, and 7.1% experienced digestive symptom. Only 9 (3.6%) patients stopped taking the drugs due to drug-related severe adverse events. CONCLUSION : DCV and ASV therapy showed a high efficacy and low rate of adverse events. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
ja : 秋田医学
en : Akita journal of medicine
巻 44,
号 3/4,
p. 101-109,
発行日 2018-03
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0386-6106 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN00009294 |
| 出版者 |
|
|
出版者 |
秋田医学会 |
|
言語 |
ja |
akitai44_3_4(101) (787.9 kB)
